A clear, evidence-based guide comparing the leading personalized brain stimulation therapies — MeRT, PeakLogic, and SynaptiQ — for autism spectrum disorder, ADHD, anxiety, and beyond.
Imagine a therapy that reads your brain's unique electrical activity, then gently guides it toward healthier patterns — without drugs, without surgery, without side effects. That's exactly what personalised transcranial magnetic stimulation therapy does.
Unlike standard transcranial magnetic stimulation protocols that apply a one-size-fits-all approach, the new generation of personalised neuromodulation begins with a quantitative EEG (qEEG) — a detailed "brain map" that captures your individual neural rhythms. From this data, a custom stimulation protocol is designed specifically for you, targeting the precise regions and frequencies that need recalibration.
Your unique neural activity is recorded and analysed before any treatment begins — creating a true personalised baseline.
Magnetic pulses are precisely directed at specific brain regions shown to be dysregulated in your individual scan.
Protocols are refined throughout treatment based on ongoing response data — not a rigid fixed plan.
Non-invasive, painless and drug-free. A genuine clinical alternative for those seeking to reduce pharmacological burden.
The scientific community has been watching closely. A growing body of peer-reviewed research — from leading neuroscience institutions across North America and Europe — has consistently demonstrated meaningful clinical benefits for conditions that have historically been difficult to treat.
Conditions where personalised transcranial magnetic stimulation has shown significant clinical evidence include:
Research highlights that personalised transcranial magnetic stimulation — beyond the standard protocols approved for depression — can modulate brain connectivity, strengthen neuroplasticity, and reduce symptoms without the systemic side effects that accompany most pharmacological approaches. For autism specifically, studies have pointed to improvements in social communication, repetitive behaviours, and emotional regulation.
▲ Real patient experience with personalised transcranial magnetic stimulation therapy — what families are reporting
There are currently three main providers of personalised transcranial magnetic stimulation. Understanding their differences — in technology, location, and accessibility — is the first step toward making an informed decision.
When every factor is laid out clearly — cost, location, technology, and approach — the picture becomes clearer for European families and patients.
| Factor | MeRT | PeakLogic | SynaptiQ Europe |
|---|---|---|---|
| Location | USA / Portugal / UK | USA only | Spain 🇪🇸 |
| qEEG Personalisation | ✓ | ✓ | ✓ |
| Technology Level | High | High | High (Netherlands) |
| Cost Estimate | €8,000–€15,000 | €10,000–€18,000 | From €2,500 / 2wk |
| Accessible from Europe | Partial | ✗ | ✓ Fully |
| Gut-Brain Integration | Limited | Limited | ✓ Included |
| Progressive Investment | ✗ | ✗ | ✓ |
| European Clinical Standards | Partial | ✗ | ✓ Full EU |
One of the most exciting developments in autism and mental health science over the past decade is the growing understanding of the gut-brain connection. The intestinal microbiome doesn't just affect digestion — it directly influences neurological function, emotional regulation, and the production of neurotransmitters like serotonin.
Advanced protocols that integrate gut-brain axis assessment go beyond the brain itself. They evaluate intestinal microbiota composition, design targeted nutritional interventions, and address neuroinflammatory pathways — all alongside the neuromodulation treatment.
The scientific rationale is compelling: if the gut is producing suboptimal neurotransmitter environments, personalised transcranial magnetic stimulation alone is working against an ongoing systemic challenge. By addressing both axes simultaneously, the potential for sustained improvement is meaningfully greater.
Personalised transcranial magnetic stimulation therapy may be a meaningful option if any of the following resonates with your situation — whether you're exploring options for yourself, your child, or a loved one.
For years, families across Europe faced a difficult dilemma: either invest enormous sums in travel and treatment in the United States, or make do with more limited local options. That gap is closing rapidly heading into 2026–2027.
Spain — and specifically the team behind SynaptiQ at Advanced Neuro Center — is demonstrating that it's possible to bring truly cutting-edge personalised neuromodulation within reach of European patients. The technology is equivalent. The clinical standards are rigorous. And the accessibility is genuinely transformative for families who previously had no viable local pathway.
For international patients, Spain also offers a highly practical setting: excellent connectivity, a temperate climate conducive to recovery, and healthcare infrastructure that meets the highest European Union standards.